FDA-approved
Sexual & reproductive
Goserelin
Evidence
FDA approved
Class
GnRH agonist
KEY TAKEAWAY
Goserelin is a synthetic GnRH agonist delivered as a small implant. It is sold as Zoladex. The FDA approved goserelin (Zoladex) in 1989, and it is now approved for several hormone-sensitive cancers and gynecologic conditions.
Written by the Veylo editorial team · Updated
November 2026
What it is
GnRH agonist
Approved for
Prostate cancer, breast cancer, endometriosis and uterine fibroids
Key fact
The FDA approved goserelin (Zoladex) in 1989, and it is now approved for several hormone-sensitive cancers and gynecologic conditions.
Route
Implant under the skin of the abdomen every 1 to 3 months
Evidence strength
FDA approved
Goserelin is a synthetic GnRH agonist delivered as a small implant. It is sold as Zoladex.
It first stimulates and then desensitizes GnRH receptors, which lowers sex hormone production over time.
The FDA approved goserelin (Zoladex) in 1989, and it is now approved for several hormone-sensitive cancers and gynecologic conditions.
Prostate cancer, breast cancer, endometriosis and uterine fibroids.
Hot flashes, reduced libido and bone density loss are common. Hormone levels can briefly rise at the start of treatment.
U.S. FDA prescribing information for Goserelin. DailyMed, National Library of Medicine.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.